Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
Stock Information for Atossa Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.